Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

NCT04841512 | Withdrawn Phase 1 FDA Drug

• 1 other identifier: XT-150-1-0301
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Preliminary safety and efficacy of XT-150 in the synovial capsule of osteoarthritic facet joints in the vertebra of the spine.

Conditions

Osteoarthritis, Spine

Keywords

gene therapy; non-viral plasmid; osteoarthritis

Outcome Measures

Primary Outcomes (1)

• Visual analog scale (VAS)

  0 - 100, 100 worst possible pain

  6 months

Secondary Outcomes (1)

• Oswestry Disability Index

  6 months

Study Arms (3)

Placebo

PLACEBO COMPARATOR

Sterile phosphate-buffered saline for injection Single 1mL injection into the facet joint

Biological: XT-150

XT-150 Dose #1

EXPERIMENTAL

Lower dose of XT-150 sterile solution for injection Single 1 mL injection into the facet joint

Biological: XT-150

XT-150 Dose #2

EXPERIMENTAL

Higher dose of XT-150 sterile solution for injection Single 1 mL injection into the facet joint

Biological: XT-150

Interventions

XT-150 BIOLOGICAL

non-viral Plasmid DNA encoding an IL-10 variant transgene

Placebo; XT-150 Dose #1; XT-150 Dose #2

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female, between 18 and 90 years of age, inclusive.
• Sufficiently severe facet arthropathy (OA) of lumbar facets as determined by imaging, eg. CT or MRI, to establish an underlying basis of disease, as determined by usual bony and ligamentous signs of OA.
• Complaint of nociceptive, mechanical pain of lumbar spine, in particular pain localized to paramedian axis as opposed to midline or radicular. Radicular pain as a secondary finding may be allowed if it is addition to mechanical pain and can be clinically distinguished by subject
• Low Back Pain (LBP) worsened by activity or motion of region
• Have had a positive diagnostic facet pain block with lignocaine; admittance if subject gains 50% relief of pain within 30 minutes of test injection
• Be free of local or intra-articular infection, tumor or other causes of localized LBP, for example Including spondylolysis/pars defect, and adjacent vertebral body compression fracture based on MRI evaluation.
• Symptomatic disease because of osteoarthritis, established by imaging of facet joint and defined as a worst pain of at least 40 at any time during the preceding week (based on scale of 0 to 100, with 100 representing "pain as bad as you can imagine") using Visual Analog Scale (VAS).
• Stable analgesic regimen during the 4 weeks prior to enrollment.
• Inadequate pain relief (minimum ≥50 mean on VAS with prior therapies lasting ≥3 months.
• In the judgment of the Investigator, acceptable general medical condition
• Male and female participants who are heterosexually active and not surgically sterile or post-menopausal must agree to use effective contraception, including abstinence, for the duration of the study and for 3 months after the study is completed
• Have suitable facet joint anatomy for intra-articular injection
• Willing and able to return for the follow-up (FU) visits
• Able to reliably provide pain assessment (FAST test score R2≥0.7)
• Able to read and understand study instructions, and willing and able to comply with all study procedures

You may not qualify if:

• Hypersensitivity, allergy, or significant reaction to any ingredient of the study drug, including double-stranded DNA, mannose, and sucrose
• Scheduled surgical procedure or nerve ablation to joint within the next 6 months; participant agrees not to schedule a surgical procedure, nerve ablation, or added facet injection within 6 months of study treatment
• High peri-operative risks which in the judgment of the investigator preclude a safe facet joint injection procedure (e.g. extreme obesity putting injection accuracy at risk, etc.)
• Current treatment with immunosuppressive (systemic corticosteroid therapy \[equivalent to \>10mg/day prednisone\] or other strong immunosuppressant)
• History of immunosuppressive therapy; high-potency systemic steroids in the last 3 months.
• Currently receiving systemic chemotherapy or radiation therapy for malignancy
• Clinically significant hepatic disease as indicated by clinical laboratory results ≥3 times the upper limit of normal for any liver function test (e.g., aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase)
• Severe anemia (Grade 3; hemoglobin \<8.0 g/dL, \<4.9 mmol/L, \<80 g/L; transfusion indicated), Grade 1 white cell counts (lymphocytes \<LLN - 800/mm3; \<LLN - 0.8 x 109 /L, neutrophils \<LLN - 1500/mm3; \<LLN - 1.5 x 109 /L)
• Positive serology with reflex for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus within 4 weeks of commencing the study
• Significant neuropsychiatric conditions; dementia, major depression, or altered mental state that in the opinion of the Investigator will interfere with study participation
• Current treatment with systemic antibiotics or antivirals (EXCEPTION: topical treatments)
• Current treatment with anticoagulants, other than low-dose aspirin
• Known or suspected history of active alcohol or intravenous/oral drug abuse within 1 year before the screening visit
• Use of any investigational drug or device within 1 month before enrollment or current participation in a trial that included intervention with a drug or device; or currently participating in an investigational drug or device study.
• Any condition that, in the opinion of the Principal Investigator, could compromise the safety of the participant, the participant's ability to communicate with the study staff, or the quality of the data

Sponsors & Collaborators

• Xalud Therapeutics, Inc.: lead

Study Sites (1)

Alfred Health

Melbourne, Victoria, 3004, Australia

Location

MeSH Terms

Conditions

Osteoarthritis, Spine; Osteoarthritis

Condition Hierarchy (Ancestors)

Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Rheumatic Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Unblinded pharmacy, blinded clinical staff for administration and assessments
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 7, 2021
• First Posted: April 12, 2021
• Study Start: October 1, 2021
• Primary Completion: March 1, 2022
• Study Completion: March 1, 2022
• Last Updated: March 17, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)